GlaxoSmithKline Pharmaceuticals Limited is ... 2021 Company launched the Nucala, first anti-IL5 drug, auto-injector device in India. It launched Trelegy Ellipta, the countrys first single inhaler ...

AZ is hoping that Fasenra (benralizumab) could join rival drugs from Sanofi/Regeneron and GlaxoSmithKline as ... the US market by GSK's IL-5 inhibitor Nucala (mepolizumab) last year.

They also need to be having at least four severe asthma attacks per year and either have not responded to, or be unable to tolerate, other biologic drugs like GlaxoSmithKline's Nucala (mepolizumab).

TD Cowen analyst Steve Scala maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of $45.00. The ...

J.P. Morgan analyst James Gordon maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.40.

GSK plc GSK announced that the FDA has accepted its regulatory filing, seeking the approval of a new indication for Nucala ...

The US Food and Drug Administration (FDA) has accepted a submission from GSK to review a new indication of Nucala ...

After previously rejecting an application for this indication, the US Food and Drug Administration (FDA) has now accepted for ...

US FDA accepts GSK’s submission for the use of Nucala to treat patients with chronic obstructive pulmonary disease: London, UK Wednesday, December 11, 2024, 10:00 Hrs [IST] GSK ...

In addition, GSK said its Blenrep drug has been approved for priority review in China to treat sufferers of myeloma, a bone marrow cancer. The regulatory submission is supported by phase III ...

London open The FTSE 100 is expected to open eight points higher on Monday, having closed down 0.49% on Friday at 8,308.61.

It was a busy week in the biotech sector with lots of data readouts. This apart, the key regulatory updates and pipeline news ...